Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK

por Bowrin, Kevin, Briere, Jean-Baptiste, Levy, Pierre, Millier, Aurélie, Tardu, Jean, Toumi, Mondher
Publicado 2020

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain

por Escobar Cervantes, Carlos, Martí-Almor, Julio, Cabeza, Alejandro Isidoro Pérez, Bowrin, Kevin, Llorac Moix, Aleix, Genís Gironès, Mar, Gasche, David, Millier, Aurélie, Tardu, Jean, Toumi, Mondher, Briere, Jean-Baptiste
Publicado 2022